Cooperation projects

 

InKemia IUCT group has been, since its constitution in 1997 until now, executing over 35 of its own R&D projects framed in the different areas financed by the public administration in collaboration with European projects (Collaborative Research Program, CRAFT, INTAS, TEMPUS, Marie Curie), besides national programs (PROFIT, TORRES QUEVEDO) and regional programs  (CIDEM, GENERALITAT DE CATALUNYA). This participation in research programs reaches its high point in March 2004 with the European project SOLVSAFE, of which InKemia IUCT group is coordinator and which involves 22 partners, 15 companies and 22 company associations.

InKemia IUCT group also offers companies the possibility to execute projects in cooperation.

 

INTERNATIONAL COOPERATION PROJECTS

 

01 Technological development in drug discovery laboratories using combinatorial chemistry/parallel synthesis and HTA system (COMBINATORIA)
EUREKA Program of V PM of the European Union (File Nº E! 2900) 

02 Eccofficient optimization of biodiesel production by innovative methods and utilization of by-products (ECO-Diesel)
CRAFT Program of the V European Union Frame Program (File Nº CRAFT-1999-72319). 

03 Identification, synthesis and biological Screening of New Drug Leads with a Rational-Drug Design Approach for Bradykinin Antagonism as anti-asthmatic therapeutic Strategy (BRADIKININA)
Project in cooperation with UPC and financed by the Fundació Marató TV3 foundation (respiratory diseases) (File Nº E041931)
Education and Science ministry, PROFIT program (File Nº CIT-090100-2005-33)

04 Advanced Safer Solvents for Innovative Industrial Eco- Processing (SOLVSAFE) Integrated project where IUCT acts as coordinator
Project approved in the NMP IP-SMEs program of the VI European Union Frame Program.  (File Nº: 011774-2)

05 High Throughput Research: Towards a fast biobased discovery and Screening of new drug targeting neoplasic and metastasic activity (DISC-SCREEN)
Project in cooperation where IUCT acts as coordinator
Eurostars Program of the European Union (File Nº E!4400)
Financed through the CDTI Interempresas Internacional program (File Nº CIIP-20091013)

06 Development of novel treatment for myotonic dystrophy: in vivo discovery (Malalties minoritàries)
Project in cooperation with IQS and UV.
Financed by the Fundació Marató TV3 foundation (Minority Diseases) (File Nº 100230/31/32).

07 Prevention of prosthetic cardiac valve complication through the modification of natural anti-carbohydrate antibodies (TRANSLINK)
Project in cooperation with IDIBELL, IUCT, UCL and AOP.
Financed by the VII European Union Frame Program (File Nº 603049-1)

08 Novel Biofocused targeting of nucleoside analogues as enhanced anticancer therapy (NOBITAN)
Project in cooperation with Leitat and JPT.
Project approved by the Eurotransbio 2011 program of the European Union (File Nº: ETB-2011-43)
Financed by ACC1Ó of the Generalitat de Catalunya (File Nº: RDNET11-1-0004)

09 Glycerol Biorefinery Approach for the Production of High Quality Products of Industrial Value (GRAIL)
Project in cooperation with ENEA, BZN, MEGEGARA,…
Financed by the VII European Union Frame Program (File Nº: FP7-KBBE.2013.3.4-01)

10 Ecopaint bio-based formulations (ECOBIOFOR)
Inkemia participates as a RTD performer.
Financed by the VII European Union Frame Program (File Nº: 605215).

11 Sustainable industrial processes based on a C-C bond-forming enzyme platform (CARBAZYMES)
Inkemia participates as a RTD performer.
Financed by the Horizon 2020 European Union Frame Program (File Nº: H2020-LEIT-BIO-2014-1).


AMMIC, l’Acceleradora en Malalties Minoritàries de Catalunya.

Comunitat RIS3CAT NextHealth

COMRDI15‐1‐0014

The Collaborative project AMMIC was launched to face the difficulties of the treatment of rare diseases. AMMIC consist in a network of technology based companies and reputed hospitality research centres that collaborate in boosting the development of therapeutic solutions to rare diseases from the early discovery to clinical research.

Supporting


Development of food supplements to improve the quality of life of patients affected with Type 1 Myotonic Dystrophy, DM1

 

IDI-20151100

DM1 project is launched for the development of marketable products, with the possibility to be registered under food supplement regulations, to improve the quality of life of patients affected with DM1.

Supporting